LB Pharmaceuticals (LBRX) Fundamental Analysis: Revenue, Earnings & Valuation

5.94 / 10

Netural

Fundamental metrics score 5.94/10, rated Neutral. Strengths include low current‑liabilities ratio (64.0%) and robust interest coverage (35.1%). PB‑ROE and Revenue‑MV contribute positively, while Asset‑MV is a weakness. Overall fundamentals are balanced but not compelling.

Analysis Checks(9/10)

Revenue-MV

Value-0.28

Score3/3

Weight41.72%

1M Return8.11%

Total operating revenue (YoY growth rate %)

Value134.00

Score2/3

Weight0.57%

1M Return0.13%

Inventory turnover ratio

Value103.94

Score2/3

Weight-4.76%

1M Return-1.18%

Current liabilities / Total liabilities (%)

Value64.02

Score2/3

Weight1.61%

1M Return0.36%

PB-ROE

Value0.04

Score3/3

Weight52.54%

1M Return9.18%

Long-term debt to working capital ratio (%)

Value0.01

Score2/3

Weight-1.48%

1M Return-0.35%

Interest coverage ratio (EBIT / Interest expense) (%)

Value35.11

Score2/3

Weight-4.84%

1M Return-1.17%

Operating revenue (YoY growth rate %)

Value177.16

Score2/3

Weight0.23%

1M Return0.05%

Cost of sales ratio (%)

Value64.41

Score2/3

Weight-4.57%

1M Return-1.13%

Asset-MV

Value-0.49

Score0/3

Weight18.96%

1M Return4.00%

Is LBRX undervalued or overvalued?

LBRX scores 5.94/10 on fundamentals and holds a Fair valuation at present. Backed by its -15.70% ROE, 0.00% net margin, -28.37 P/E ratio, 2.37 P/B ratio, and 98.22% earnings growth, these metrics solidify its Netural investment rating.